3月9日,诺诚健华(688428/09969)发布公告,近日公司在2025年美国皮肤病学会(AAD)年会上以重磅口头报告的形式,介绍了关于治疗银屑病的新药ICP-488的临床试验数据。研究结果显示,ICP-488在每天一次6毫克和9毫克的剂量下,均对银屑病患者展现出显著疗效,并且具有良好的安全性和耐受性。在129例银屑病患者中,按1:1:1比例随机分为三组,经过12周的治疗后,6毫克剂量组和9毫克...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.